AU6137396A - Immunosuppressant - Google Patents

Immunosuppressant

Info

Publication number
AU6137396A
AU6137396A AU61373/96A AU6137396A AU6137396A AU 6137396 A AU6137396 A AU 6137396A AU 61373/96 A AU61373/96 A AU 61373/96A AU 6137396 A AU6137396 A AU 6137396A AU 6137396 A AU6137396 A AU 6137396A
Authority
AU
Australia
Prior art keywords
quinoline
ethyl
dimethoxyphenyl
group
dimethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61373/96A
Other languages
English (en)
Inventor
Haruhiko Makino
Yoshikazu Ohta
Takashi Sohda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU6137396A publication Critical patent/AU6137396A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU61373/96A 1995-09-13 1996-06-19 Immunosuppressant Abandoned AU6137396A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23570495 1995-09-13
JP7-235704 1996-06-19
PCT/JP1996/001693 WO1997009984A1 (en) 1995-09-13 1996-06-19 Immunosuppressant

Publications (1)

Publication Number Publication Date
AU6137396A true AU6137396A (en) 1997-04-01

Family

ID=16990000

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61373/96A Abandoned AU6137396A (en) 1995-09-13 1996-06-19 Immunosuppressant

Country Status (10)

Country Link
EP (1) EP0850061A1 (pt)
KR (1) KR19990044618A (pt)
CN (1) CN1195988A (pt)
AU (1) AU6137396A (pt)
BR (1) BR9610314A (pt)
CA (1) CA2226915A1 (pt)
HU (1) HUP9900169A2 (pt)
NO (1) NO980788L (pt)
NZ (1) NZ310561A (pt)
WO (1) WO1997009984A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0941987A1 (de) * 1998-03-13 1999-09-15 Lonza A.G. Verfahren zur Herstellung von 2-Amino-4,5,3',4'-tetramethoxybenzophenon
WO1999064400A1 (en) * 1998-06-12 1999-12-16 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
EP1277740A1 (en) * 1998-06-12 2003-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of p38
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
ATE380027T1 (de) 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
EP2680006A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Treatment for Amyotrophic Lateral Sclerosis
CN102050780B (zh) * 2010-11-18 2012-05-02 中国科学院昆明植物研究所 喹啉衍生物,其药物组合物及其用途
WO2017151947A1 (en) * 2016-03-02 2017-09-08 George Robert Pettit 4-azapodophylotoxins compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3014099B2 (ja) * 1987-08-26 2000-02-28 バイオジェン インコーポレイテッド 生物的材料、生物的材料の生産およびこの種の材料の治療への使用方法
KR0148009B1 (ko) * 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
JP2863265B2 (ja) * 1989-05-19 1999-03-03 ハダサ メディカル オーガニゼーション インターロイキン１インヒビター
US6238875B1 (en) * 1991-03-12 2001-05-29 The Scripps Research Institute Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1
TW232013B (pt) * 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
WO1994007498A1 (en) * 1992-10-07 1994-04-14 Sumitomo Pharmaceuticals Company, Limited Pharmaceutical composition for inhibiting tumor necrosis factor production
JPH06340658A (ja) * 1993-04-08 1994-12-13 Kyowa Hakko Kogyo Co Ltd ベンゾイミダゾール誘導体
IL111743A0 (en) * 1993-12-08 1995-01-24 Intermune Life Sciences Inc Recombinant genes expressing pp14

Also Published As

Publication number Publication date
BR9610314A (pt) 1999-07-06
KR19990044618A (ko) 1999-06-25
WO1997009984A1 (en) 1997-03-20
NO980788L (no) 1998-03-31
CA2226915A1 (en) 1997-03-20
NO980788D0 (no) 1998-02-25
EP0850061A1 (en) 1998-07-01
CN1195988A (zh) 1998-10-14
HUP9900169A2 (hu) 2000-03-28
NZ310561A (en) 1999-07-29

Similar Documents

Publication Publication Date Title
CA3210224A1 (en) Cdk inhibitors and methods of use thereof
JP5830094B2 (ja) 置換イミダゾ［１，２−ａ］ピリミジンおよび−ピリジン
IL254435B1 (en) A combination of a BTK inhibitor, an mTOR kinase inhibitor and an immunomodulatory drug and its uses in the treatment of lymphoid malignancy
CZ292349B6 (cs) Heterocyklická sloučenina, způsoby její přípravy a použití a farmaceutická kompozice s jejím obsahem
KR20030061855A (ko) 자이라제 억제제 및 이의 용도
CZ292093B6 (cs) Farmaceutický přípravek
WO2013101281A1 (en) Methods and compositions for treating parkinson's disease
CA3181415A1 (en) Azalactam compounds as hpk1 inhibitors
CN114437035A (zh) 一种抑制并降解irak4的化合物及其药物组合物和药学上的应用
CA3196287A1 (en) Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof
CA3155569A1 (en) Polyheterocyclic modulators of sting (stimulator of interferon genes)
AU6137396A (en) Immunosuppressant
CA3225285A1 (en) Pi3k.alpha. inhibitors and methods of use thereof
US20180318304A1 (en) Methods of Using BTK Inhibitors to Treat Dermatoses
CN114805351B (zh) 作为pi3k/mtor抑制剂的带有酰胺基的吡啶基取代的稠合喹啉化合物
JPH1067658A (ja) 免疫抑制剤
JP3917821B2 (ja) チエノピリジン誘導体、その製造法および用途
CN116583518A (zh) 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用
CA3183668A1 (en) Azetidine cyclic ureas
CN113214230A (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CN113620976B (zh) 噻唑并嘧啶类化合物及其制备方法、用途和药物组合物
CN116096721A (zh) 作为新型选择性flt3抑制剂的1h-咪唑并[4,5-h]喹唑啉化合物
CA3179395A1 (en) New pyrazine compound
CN115919859A (zh) 一种杂芳基衍生物的药物组合物及其在医药上的应用
JP6851826B2 (ja) がんの治療のためのｐｉｍキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted